Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry

References

• Fernandez-Cruz L. Periampullary carcinoma. In: Holzheimer R, Mannick J, editors. Surgical treatment: evidence-based and problem-oriented. Munich, Germany: Zuckschwerdt; 2001.
   Google Scholar
• Sarmiento JM, Nagomey DM, Sarr MG, et al. Periampullary cancers: are there differences? Surg Clin North Am. 2001;81(3):543–555.
   PubMed Web of Science ®Google Scholar
• Meijer LL, Alberga AJ, de Bakker JK, et al. Outcomes and treatment options for duodenal adenocarcinoma: a systematic review and Meta-Analysis. Ann Surg Oncol. 2018;25(9):2681–2692.
   PubMed Web of Science ®Google Scholar
• Pancreascarcinoom. Landelijke richtlijn: Nederlandse Vereniging voor Heelkunde. 2019. Available from: https://dpcg.nl/wp-content/uploads/2020/04/Richtlijn_Pancreascarcinoom_2019.pdf
   Google Scholar
• Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v56–68.
   PubMedGoogle Scholar
• Galweg- en galblaascarcinoom. Landelijke richtlijn. Landelijke werkgroep Gastro-intestinale tumoren; 2013. Available from: Galweg- en Galblaascarcinoom - Algemeen - Richtlijn - Richtlijnendatabase
   Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):v28–v37.
   PubMedGoogle Scholar
• Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–1027.
   PubMed Web of Science ®Google Scholar
• Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564.
   PubMed Web of Science ®Google Scholar
• Hester CA, Dogeas E, Augustine MM, et al. Incidence and comparative outcomes of periampullary cancer: a population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012. J Surg Oncol. 2019;119(3):303–317.
   PubMed Web of Science ®Google Scholar
• Percy C, Holten V, Muir CS, et al. 1990. International classification of diseases for oncology. Percy C, Holten V, Muir CS, editors. 2nd ed. World Health Organization.
   Google Scholar
• Edge SB, Byrd DR, Carducci MA, et al. AJCC cancer staging manual. Vol. 7. New York (NY): Springer; 2010.
   Google Scholar
• Amin MB, Edge SB. American joint committee on C. AJCC cancer staging manual. New York (NY): Springer; 2017.
   Google Scholar
• Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–1773.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• de Jong EJM, van der Geest LG, Besselink MG, et al. Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study, HPB, 2022.
   Google Scholar
• Colorectaal Carcinoom (CRC). Nederlandse Vereniging voor Heelkunde; 2020. Available from: Startpagina - Colorectaal carcinoom (CRC) - Richtlijn - Richtlijnendatabase.
   Google Scholar
• Argiles G, Tabernero J, Labianca R, et al. Localised Colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–1305.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21(9):1786–1793.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Moore MJ, Cox TF, et al. Ampullary cancer ESPAC-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2011;29(18):LBA4006–LBA4006.
   Web of Science ®Google Scholar
• Bonet M, Rodrigo A, Vazquez S, et al. Adjuvant therapy for true ampullary cancer: a systematic review. Clin Transl Oncol. 2020;22(8):1407–1413.
   PubMed Web of Science ®Google Scholar
• Moekotte AL, Malleo G, van Roessel S, et al. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg. 2020;107:1171–1182.
   PubMed Web of Science ®Google Scholar
• Pea A, Riva G, Bernasconi R, et al. Ampulla of vater carcinoma: molecular landscape and clinical implications. World J Gastrointest Oncol. 2018;10(11):370–380.
   PubMed Web of Science ®Google Scholar
• Casolino R, Paiella S, Azzolina D, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence Meta-Analysis. J Clin Oncol. 2021;39(23):2617–2631.
   PubMed Web of Science ®Google Scholar
• Bakens MJ, Geest LG, Putten M, et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 2016;5(10):2825–2831.
   PubMed Web of Science ®Google Scholar
• Mackay TM, Smits FJ, Roos D, et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB (Oxford). 2020;22(2):233–240.
   PubMed Web of Science ®Google Scholar
• Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–512.
   PubMed Web of Science ®Google Scholar